Search company, investor...

Interventional Spine

i-spineinc.com

Founded Year

2000

Stage

Debt - II | Alive

Total Raised

$42.05M

Last Raised

$3.44M | 10 yrs ago

About Interventional Spine

Interventional Spine, fka Triage Medical, is a medical device company focused on the design, development, and marketing of patented percutaneous systems to treat lower back pain. Interventional Spine's expandable cage technology provides optimal tactile feedback for the surgeon, and features a continuously adjustable design that allows the surgeon to customize the device height to the patient's anatomy. The implants are designed to maximize bone graft contact and containment, which helps promote bone growth and fusion. The company was founded in 2000 and is based in Irvine, California.

Headquarters Location

13700 Alton Parkway Suite 160

Irvine, California, 92618,

United States

949-472-0006

Missing: Interventional Spine's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Interventional Spine's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Interventional Spine

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Interventional Spine is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Interventional Spine Patents

Interventional Spine has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/18/2013

9/6/2022

Bones of the vertebral column, Orthopedic surgical procedures, Skeletal system, Bones of the thorax, Neurosurgery

Grant

Application Date

3/18/2013

Grant Date

9/6/2022

Title

Related Topics

Bones of the vertebral column, Orthopedic surgical procedures, Skeletal system, Bones of the thorax, Neurosurgery

Status

Grant

Latest Interventional Spine News

08:07 EDT Stryker receives FDA clearance for OptaBlate™ Bone Tumor Ablation System

Sep 20, 2022

News provided by Share this article Share this article Stryker's first bone tumor ablation system with patented microinfusion technology offers a reliable solution for people living with painful metastatic tumors PORTAGE, Mich., USA, Sept. 20, 2022 /PRNewswire/ -- Stryker ( NYSE: SYK ), one of the world's leading medical technology companies, announced today that its OptaBlate bone tumor ablation system (OptaBlate) received 510(k) clearance from the U.S. Food and Drug Administration. The addition of the OptaBlate technology to Stryker's Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures. Stryker's first bone tumor ablation system with patented microinfusion technology offers a reliable solution for people living with painful metastatic tumors "Stryker's new bone tumor ablation (BTA) system is a significant improvement on existing technology and builds on Stryker's IVS portfolio," said Dr. Anthony Brown, a Vascular and Interventional Radiologist at Radiology Imaging Associates, CO. "There is no more deserving patient population for our attention and intervention; OptaBlate will change lives." As Stryker's first Interventional Oncology technology, OptaBlate optimizes all aspects of the procedure—from set-up to ablation. Featuring four probes and Stryker's unique and patented microinfusion technology*, OptaBlate allows physicians to easily customize their procedure and reduce ablation time by three minutes.1 Specific key features of the system include: Treatment of two vertebral body levels at once using a bipedicular approach Quicker, more consistent ablation1 Microinfusion technology, which keeps the zone hydrated, reducing impedance errors and preventing charring1 "Our commitment to our customers and understanding their needs has never been stronger. The collaboration has helped us to develop a more efficient bone tumor ablation system to address their unmet needs," said Greg Siller, Vice President and General Manager, Interventional Spine business, Stryker. "OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning." Stryker's Interventional Spine business will introduce its OptaBlate as part of its minimally invasive portfolio at the North American Spine Society Annual Meeting, Oct. 12-15, in Chicago, IL. (Booth #4211). About Stryker's Interventional Spine We are working to advance interventional care from diagnosis to delivery. For more information, visit strykerivs.com  and connect with us on LinkedIn , Twitter , VuMedi , and Vimeo . About Stryker Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 100 million patients annually. More information is available at www.stryker.com . Media contact * As of 9/14, OptaBlate features the only microinfuser on the market Dr. Anthony Brown is a paid consultant of Stryker. His statements represent his own opinions based on personal experience and are not necessarily those of Stryker. Individual results may vary. This document is intended solely for the use of healthcare professionals. A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. We do not dispense medical advice and recommend that surgeons be trained in the use of any particular product before using it in surgery. The information presented is intended to demonstrate Stryker's products. A physician must always refer to the package insert, product label and/or instructions for use, including the instructions for cleaning and sterilization (if applicable), before using any of Stryker's products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your representative if you have questions about the availability of Stryker's products in your area. Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: OptaBlate and Stryker. All other trademarks are trademarks of their respective owners or holders. The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker's trademark or other intellectual property rights concerning that name or logo. D0000220767

Interventional Spine Frequently Asked Questions (FAQ)

  • When was Interventional Spine founded?

    Interventional Spine was founded in 2000.

  • Where is Interventional Spine's headquarters?

    Interventional Spine's headquarters is located at 13700 Alton Parkway, Irvine.

  • What is Interventional Spine's latest funding round?

    Interventional Spine's latest funding round is Debt - II.

  • How much did Interventional Spine raise?

    Interventional Spine raised a total of $42.05M.

  • Who are the investors of Interventional Spine?

    Investors of Interventional Spine include Wexford Capital, HBM Healthcare Investments, Japan Asia Investment Group, Frantz Medical Ventures, HBM Partners and 6 more.

  • Who are Interventional Spine's competitors?

    Competitors of Interventional Spine include MicroTransponder, Flowonix Medical, ValenTx, Zyga Technology, Entellus Medical and 15 more.

Compare Interventional Spine to Competitors

MicroTransponder Logo
MicroTransponder

MicroTransponder is a global medical device company committed to developing research-based neuroscience solutions. The company focuses on restoring independence and dignity for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder's FDA-approved Vivistim® Paired VNS™ System is a clinically-proven medical technology that generates more improvement in upper limb function than rehabilitation alone for stroke survivors after 6 weeks of in-clinic therapy. MicroTransponder was founded in 2007 and is based in Austin, Texas.

Flowonix Medical Logo
Flowonix Medical

Flowonix designs, develops, and deploys targeted drug delivery platforms whose sole purpose is to provide physicians an optimal solution for the treatment of their patients' numerous neurological disorders.

D
Disc Dynamics

Disc Dynamics has developed the DASCORTM Disc Arthroplasty System, an innovative, minimally invasive nucleus replacement treatment for patients suffering from chronic low back pain caused by Degenerative Disc Disease (DDD).

S
Spinal Restoration

Spinal Restoration restores patients' lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop and gain regulatory approval of the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain, based on solid scientific and clinical evidence.

S
SpineLab

Spinelab is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine for the treatment of degenerative lumbar spine disease.

A
Applied Spine Technologies

Applied Spine Technologies is a spine company focused on developing implantable dynamic stabilization systems for the treatment of chronic back pain.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.